Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Fierce Pharma
FDA investigates 2 deaths after Sarepta Duchenne gene therapy
The agency is investigating two Duchenne muscular dystrophy patient deaths following treatment with Sarepta Therapeutics’ Elevidys.
Angus Liu
Jun 25, 2025 10:26am
Fierce Pharma
2nd patient dies after Sarepta's DMD gene therapy Elevidys
Jun 16, 2025 10:58am
RegenXBio links DMD gene therapy to improved outcomes
Jun 5, 2025 8:52am
Keros culls phase 2 PAH program, 70 staff roles
May 29, 2025 10:10am
PepGen ends all DMD work after phase 2 trial falls flat
May 28, 2025 5:30pm
Capricor shares turn red as FDA announces deramiocel adcomm plan
May 6, 2025 8:32am
